

Table SI. Patients who received GS, n (%).

	Dosing period cycle				
	2	3	5	8	10
Initial clinical TNM stage					
Stage I	2 (11.8)	0 (0)	0 (0)	1 (5.9)	0 (0)
Stage II	6 (35.3)	1 (5.9)	1 (5.9)	0 (0)	1 (5.9)
Stage III	3 (17.6)	0 (0)	2 (11.8)	0 (0)	0 (0)
Stage IV	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

GS, gemcitabine and S-1; TNM, tumor, node and metastasis.

Table SII. Patients who received GnP, n (%).

	Dosing period cycle								
	2	3	4	5	6	7	8	12	15
Initial clinical TNM stage									
Stage I	5 (17.2)	1 (3.4)	1 (3.4)	1 (3.4)	3 (10.3)	0 (0)	0 (0)	1 (3.4)	1 (3.4)
Stage II	5 (17.2)	0 (0)	2 (6.9)	1 (3.4)	1 (3.4)	1 (3.4)	1 (3.4)	1 (3.4)	0 (0)
Stage III	0 (0)	2 (6.9)	2 (6.9)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Stage IV	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

GnP, gemcitabine and nab-paclitaxel; TNM, tumor, node and metastasis.